DERM

SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.

Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million  Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz.

Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation (“Journey” or the “Company”) (NASDAQ: DERM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™  generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™  during FY2025 Payer access for Emrosi™  available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz.